Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.69 |
| ▸ | MAOB | P27338 | 4/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | GAPDH | P04406 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 7/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.57 |
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.57 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.57 |
| ▸ | ESR1 | P03372 | 1/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MIF | P14174 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23212283 | 0.83 | RAB9A (0.75) | RAB9AKDM4EMAOBALDH1A1MAPT | |
| SCHEMBL30356319 | 0.82 | RAB9A (1.00) | RAB9AKDM4EMAOBALDH1A1MAPT | |
| SCHEMBL177366 | 0.82 | RAB9A (1.00) | RAB9AKDM4EMAOBALDH1A1MAPT | |
| SCHEMBL3396561 | 0.80 | RAB9A (0.66) | RAB9AKDM4EMAOBALDH1A1MAPT | |
| SCHEMBL28664040 | 0.80 | MAOB (0.66) | RAB9AKDM4EMAOBALDH1A1MAPT | |
| SCHEMBL29517170 | 0.78 | RAB9A (0.78) | RAB9AKDM4EMAOBALDH1A1MAPT | |
| SCHEMBL5537116 | 0.78 | MAOB (0.54) | RAB9AKDM4EMAOBALDH1A1MAPT | |
| SCHEMBL27969864 | 0.74 | MIF (0.75) | RAB9AKDM4EMAOBALDH1A1MAPT | |
| SCHEMBL22132745 | 0.74 | GAPDH (1.00) | RAB9AKDM4EMAOBALDH1A1MAPT | |
| SCHEMBL8814114 | 0.74 | MAPT (1.00) | RAB9AKDM4EMAOBALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004301-A1 | Benzoxazoles Useful in the Treatment of Inflammation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-07 | — | — | US | claimed |
| EP-2102177-A1 | BENZOXAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION | Boehringer Ingelheim International GmbH (DE) | 2009-09-23 | — | — | EP | claimed |
| WO-2008071944-A1 | BENZOXAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-06-19 | — | — | WO | claimed |
| US-20100004301-A1 | Benzoxazoles Useful in the Treatment of Inflammation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-07 | — | — | US | disclosed |
| EP-2102177-A1 | BENZOXAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION | Boehringer Ingelheim International GmbH (DE) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008071944-A1 | BENZOXAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004301-A1 | Benzoxazoles Useful in the Treatment of Inflammation | IL4I1, EPX, IL4 | RAB9A 3680/4885KDM4E 1264/4885MAOB 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.